Sedivention

Sedivention GmbH is a medical technology company addressing the global obesity epidemic through a novel, minimally invasive therapeutic approach. Founded in 2021 by Dr. Ute Nollert, Dr.-Ing. Andreas Bröcker, and André Burch, the company is developing a cryo-catheter designed to offer a long-term solution for weight management. The founders combine extensive experience in medicine and engineering to pioneer this new treatment modality. The core of Sedivention's business is the development and eventual commercialization of its proprietary medical device, targeting gastroenterology specialists and clinics that perform outpatient procedures.

The company's flagship product, the Blizzard cryo-catheter, targets the physiological source of hunger. Hunger signals are transmitted from the stomach to the brain primarily via the gastric branches of the vagus nerve. Sedivention's technology uses cryoneuromodulation, a process of freezing these specific nerve branches from inside the stomach. The procedure is designed to be a one-time, outpatient intervention comparable to a standard gastroscopy, taking approximately 20 minutes to complete. It involves inserting the catheter, positioning a balloon in the stomach, and then activating the cryo-ablation process to interrupt the nerve signals. A key benefit of this approach is that it is minimally invasive, leaves no implants or scars, and avoids the complications and costs associated with bariatric surgery.

Sedivention has made significant progress since its inception, including the development and successful initial testing of a device prototype for safety and efficacy. In November 2024, the company secured €800,000 in a pre-seed funding round led by High-Tech Gründerfonds (HTGF) to advance product development and initiate preclinical studies. The company has also gained recognition by winning several business plan competitions and being accepted into accelerator programs like the Creative Destruction Lab (CDL). With the new capital, Sedivention aims to further refine its prototype into a clinically viable, mass-producible product, with the goal of completing initial studies and achieving market entry within five years.

Keywords: obesity treatment, cryoneuromodulation, medical device, weight management, vagus nerve, cryo-ablation, minimally invasive therapy, gastroscopy, interventional obesity therapy, bariatric surgery alternative, hunger reduction, cryo-catheter, Blizzard catheter, outpatient procedure, MedTech, gastroenterology, High-Tech Gründerfonds, Ute Nollert, Andreas Bröcker, André Burch, weight loss solution